Indoco Remedies Limited
BSE:532612 주식 보고서
Indoco Remedies 대차 대조표 상태 Indoco Remedies 의 총 주주 지분은 ₹10.9B 이고 총 부채는 ₹8.2B, 이는 부채 대 자기자본 비율을 75.2% 로 가져옵니다. 총자산과 총부채는 각각 ₹23.9B 및 ₹13.0B 입니다. Indoco Remedies 의 EBIT는 ₹938.1M 이며 이자보상배율은 1.9 입니다. ₹417.3M 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보 이자 보상 비율 1.9x 현금 ₹417.30m 주식 ₹10.89b 총 부채 ₹13.01b 총 자산 ₹23.90b
최근 재무 상태 업데이트
모든 업데이트 표시
Price target decreased by 9.0% to ₹324 Oct 25
Second quarter 2025 earnings released: ₹1.09 loss per share (vs ₹3.82 profit in 2Q 2024) Oct 25
Indoco Remedies Limited to Report Q2, 2025 Results on Oct 24, 2024 Oct 14
Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Cetirizine Hydrochloride Tablets USP, 10 mg Oct 04
Indoco Remedies Limited Declares Final Dividend for Financial Year Ended March 31, 2024 Sep 27
Dividend of ₹1.50 announced Sep 01
Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024 Aug 30
Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024 Aug 28
Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Lofexidine Tablets 0.18 Mg with Competitive Generic Therapy Designation Aug 23
First quarter 2025 earnings released: EPS: ₹0.20 (vs ₹2.62 in 1Q 2024) Jul 24
Indoco Remedies Limited to Report Q1, 2025 Results on Jul 23, 2024 Jul 10
MD & Executive Director recently bought ₹3.1m worth of stock Jun 08
Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets Jun 08
Now 21% overvalued Jun 03
Joint MD & Executive Director recently bought ₹1.2m worth of stock May 29
Price target decreased by 8.8% to ₹360 May 18
Now 24% overvalued May 14
Indoco Remedies Limited to Report Q4, 2024 Results on May 16, 2024 May 10
Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024 Mar 30
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Jan 24
Indoco Remedies Limited to Report Q3, 2024 Results on Jan 23, 2024 Jan 11
Insufficient new directors Nov 04
Indoco Remedies Limited to Report Q2, 2024 Results on Oct 19, 2023 Oct 07
Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2023 Sep 27
Indoco Remedies Limited, Annual General Meeting, Sep 26, 2023 Sep 01
First quarter 2024 earnings: EPS and revenues miss analyst expectations Jul 26
Indoco Remedies Limited to Report Q1, 2024 Results on Jul 25, 2023 Jul 15
MD & Executive Director recently bought ₹6.4m worth of stock Jun 16
MD & Executive Director recently bought ₹1.6m worth of stock Jun 12
Indoco Remedies Limited (NSEI:INDOCO) agreed to acquire a 85% stake in Florida Pharmaceutical Products, Inc. from Contract Pharmacal Corp. for $4 million. Jun 07
Indoco Remedies Limited Recommends Dividend for the Financial Year 2022-2023 May 24
Full year 2023 earnings: EPS and revenues miss analyst expectations May 24
Indoco Remedies Limited to Report Q4, 2023 Results on May 23, 2023 May 13
MD & Executive Director recently bought ₹669k worth of stock Apr 05
Insufficient new directors Apr 01
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Jan 25
Indoco Remedies Limited to Report Q3, 2023 Results on Jan 24, 2023 Jan 11
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 16
Indoco Remedies Limited Announces Executive Changes Nov 11
Indoco Remedies Limited to Report Q2, 2023 Results on Nov 10, 2022 Oct 21 Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2022
Indoco Remedies Limited Announces Anacipher CRO Clears USFDA Inspection with Zero 483S Sep 20
Upcoming dividend of ₹2.25 per share Sep 07 Indoco Remedies Limited, Annual General Meeting, Sep 22, 2022 Indoco Remedies Limited (BSE:532612) agreed to acquire 26% stake in Kanakal Wind Energy Private Limited for INR 8.64 million.
First quarter 2023 earnings released: EPS: ₹4.19 (vs ₹4.30 in 1Q 2022) Aug 10
Indoco Remedies Limited to Report Q1, 2023 Results on Aug 09, 2022 Jul 16 Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022
Full year 2022 earnings: Revenues and EPS in line with analyst expectations May 18
Full year 2022 earnings: Revenues and EPS in line with analyst expectations May 18 Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022
Indoco Remedies Limited to Report Q4, 2022 Results on May 17, 2022 Apr 23
Third quarter 2022 earnings: EPS exceeds analyst expectations Feb 02
Second quarter 2022 earnings released: EPS ₹4.52 (vs ₹2.78 in 2Q 2021) Nov 03
Upcoming dividend of ₹1.50 per share Sep 10
First quarter 2022 earnings released: EPS ₹4.30 (vs ₹1.85 in 1Q 2021) Aug 12
Consensus EPS estimates increase to ₹17.85 Aug 12
Investor sentiment improved over the past week Jul 04
Chief Financial Officer Mandar Borkar has left the company Jun 21
Full year 2021 earnings released: EPS ₹10.10 (vs ₹2.62 in FY 2020) May 27
Indoco Remedies Limited Recommends Dividend for the Financial Year 2020-2021 May 26
Price target increased to ₹361 May 11
Indoco Announces the Launch of Brinzolamide Ophthalmic Suspension 1% in the US Market by Teva Pharmaceuticals Mar 10
Third quarter 2021 earnings released: EPS ₹2.75 (vs ₹0.99 in 3Q 2020) Feb 10
New 90-day high: ₹326 Jan 19
Indoco Remedies Limited to Report Q3, 2021 Results on Feb 09, 2021 Jan 13
New 90-day high: ₹313 Jan 04
Market bids up stock over the past week Dec 04
New 90-day high: ₹290 Dec 03
Price target raised to ₹275 Nov 09
Second quarter 2021 earnings released: EPS ₹2.78 Nov 08
Indoco Remedies Limited Appoints Abhijit Yashwant Gore as an Additional Director Oct 03
Indoco Remedies Limited Announces Retirement of Sharad P Upasani as Non- Executive Independent Director Oct 01
Indoco Remedies Limited Launches FEVINDO 400 (Favipiravir 400mg Tablets) Sep 27
New 90-day high - ₹268 Sep 15
Upcoming Dividend of ₹0.30 Per Share Sep 11
New 90-day high - ₹241 Aug 03
Indoco Remedies Limited to Report Q1, 2021 Results on Aug 11, 2020 Jul 17
재무 상태 분석
단기부채: 532612 의 단기 자산 ( ₹10.3B )이 단기 부채 ( ₹8.0B ).
장기 부채: 532612 의 단기 자산( ₹10.3B )이 장기 부채 ( ₹5.0B ).
부채 대 자본 내역 및 분석
부채 수준: 532612 의 순부채 대 자기자본 비율 ( 71.4% )은 높음 으로 간주됩니다.
부채 감소: 532612 의 부채 대 자기자본 비율은 지난 5년간 32.1% 에서 75.2% 로 증가했습니다.
부채 범위: 532612 의 부채는 영업 현금 흐름 ( 27.1% )에 의해 잘 충당 되었습니다.
이자 보장: 532612 의 부채에 대한 이자 지급 은 EBIT ( 1.9 x 적용 범위)만큼 잘 덮이지 않음 입니다.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}